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Background: Treatment of articular cartilage injuries remains a difficult challenge due to the limited capacity for
intrinsic repair. Mesenchymal stem cells (MSCs) can differentiate into chondrocytes under certain culture conditions. This
study focused on the modulatory effects of parathyroid hormone (PTH) on chondrogenic differentiation from MSCs.
Methods: MSCs were treated with various concentrations of PTH under chondrogenic pellet culture condition. RNA
was isolated for real-time polymerase chain reaction (PCR) and gene expressions of collagen type II α1 chain (Col2a1),
collagen type X α1 chain, collagen type I α1 chain, SRY-box9 (Sox9), and type 1 PTH/PTHrP receptor (PTH1R) were
examined. Chondrogenic differentiation was also evaluated by histological findings.
Results: PTH had opposite effects on chondrogenesis, depending on the concentration. A low to moderate concentration
of PTH promoted chondrogenic differentiation of MSCs with increased expression of Sox9, Col2a1, and PTH1R, whereas
chondrogenesis of MSCs was inhibited rather than stimulated with a higher concentration of PTH.
Conclusion: This study provides insights into the modulatory effect of PTH on chondrogenic differentiation from MSCs
and the therapeutic potential for cartilage regeneration. Based on clinical experience regarding the efficacy and safety
of PTH for bone metabolism, PTH may also be useful clinically for cartilage repair.
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Treatment of articular cartilage injuries remains a difficult
challenge due to the limited capacity for intrinsic repair.
Tissue engineering approaches have been introduced as
treatment options for cartilage repair. Treatment efficacy
depends entirely on the cells in the grafted site, particu-
larly the small subset of stem and progenitor cells that are
capable of generating new tissue [1]. Thus, cell-based
approaches are key to successful tissue engineering [2].
Mesenchymal stem cells (MSCs) are the most com-
monly used cell source with a high self-renewal capacity,
multilineage potential, and easy isolation from several
human tissues including bone marrow [3,4]. MSCs can
differentiate into chondrocytes under certain culture con-
ditions [5,6] and have been used for cartilage regeneration* Correspondence: kumagai@yokohama-cu.ac.jp
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unless otherwise stated.medicine by many researchers [7,8]. Therefore, a number
of research efforts are directed to the isolation of progeni-
tor cells and the understanding of the mechanisms in-
volved in their chondrogenic differentiation.
Parathyroid hormone (PTH) is known as an 84-amino
acid protein that regulates bone remodeling and calcium
homeostasis. When PTH is administrated intermittently
as a pharmacological agent, exogenous PTH has been
shown to exert significant anabolic effects. Several stud-
ies indicated that PTH(1–34) also affects chondrocyte.
PTH(1–34) inhibits the terminal differentiation of ar-
ticular chondrocytes and the progression of osteoarth-
ritis (OA) [9,10]. In parallel with the suppression of
chondrocyte hypertrophy, PTH(1–34) stimulates chon-
drocyte proliferation and differentiation in the early
stage [11-15]. However, the effects of PTH on chondro-
genic differentiation of MSCs remain to be elucidated.
We hypothesized that PTH promotes early chondro-
genic differentiation from MSCs. Here, we show theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Zhang et al. Journal of Orthopaedic Surgery and Research 2014, 9:68 Page 2 of 7
http://www.josr-online.com/content/9/1/68investigation of the modulatory effect of PTH on chon-
drogenic differentiation from MSCs.
Materials and methods
Culture of MSCs
Murine bone marrow-derived MSCs (Cyagen Biosciences,
Santa Clara, CA, USA) were expanded in a monolayer
culture with mesenchymal stem cell growth medium
(GUXMX-90011, Cyagen Biosciences) supplemented with
10% fetal bovine serum, 100 units/mL penicillin, 100 μg/mL
streptomycin, and glutamine at 37°C with 5% CO2 until
the cells reached 80% confluence. The cells were then
trypsinized and frozen in liquid nitrogen for later use.
After thawing and monolayer expansion, cells at passage 5
or 6 were harvested and subjected to pellet formation and
chondrogenic differentiation.
Induction of chondrogenic differentiation and PTH
administration
Pellets of 2.5 × 105 MSCs were formed by centrifugation
at 200 g for 5 min in 15-mL centrifuge tubes or 1.5-mL
microcentrifuge tubes. After incubation at 37°C in 5%
CO2 for 4 days, pellets were transferred to 96-well U-
bottomed plates. Cells were exposed to chondrogenic
medium (high-glucose DMEM with 0.1 μM dexametha-
sone, 0.17 mM ascorbic acid-2 phosphate, 5 μg/mL insu-
lin, 5 μg/mL transferrin, 5 ng/ml selenous acid, 0.35 mM
L-proline, 100 units/mL penicillin, and 100 μg/mL strepto-
mycin) supplemented with 10 ng/mL transforming growth
factor-β3 (TGF-β3). To detect the concentration depend-
ency of PTH(1–34) treatment of TGF-β-driven chon-
drogenesis, TGF-β-enriched chondrogenic medium was
supplemented with different concentrations of PTH (0.1,
1, 10, and 100 nM). The medium was changed every 2
or 3 days. Chondrogenic pellets were harvested at 3, 7,
or 21 days.
Histological analyses
After 3 weeks of culture, pellets were fixed overnight at
4°C in 4% paraformaldehyde solution, dehydrated with
ethanol, washed with xylene, and embedded in paraffin.
Sections at 5 μm thickness were cut from the paraffin
blocks and mounted on glass slides. The sections were
deparaffinized with xylene and ethanol prior to staining.
To detect proteoglycan synthesis as an indicator of car-
tilage production, the sections were stained with Alcian
Blue according to the standard protocol. For immuno-
histochemical staining of collagen type II, the sections
were treated with 1 mg/ml hyaluronidase (Sigma, St.
Louis, MO, USA) in PBS (pH 5.0) for 30 min at room
temperature. After blocking nonspecific binding with 3%
bovine serum albumin in PBS, rabbit anti-type II colla-
gen antibody (Novus Biologicals, Littleton, CO, USA)
was incubated overnight at 4°C. The next day, slideswere washed in PBS and incubated with biotinylated anti-
rabbit IgG antibody for 45 min at room temperature. Re-
action was visualized by incubation with the avidin-biotin-
peroxidase reagent included in the Vectastain ABC Kit
(Vector Laboratories, Burlingame, CA, USA) followed by
color development with 3-3′ diaminobenzidinetetrahy-
drochloride (Dojindo, Kumamoto, Japan). Finally, the sec-
tions were counterstained with hematoxylin and mounted
with coverslips. Cartilage tissue from mouse knee joint
was used for control staining of collagen type II. Normal
rabbit IgG was used as an isotype control.
Western blot analysis
For total protein extraction, pellets were homogenized
and incubated with lysis buffer containing 20 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% NP-40, 0.1% sodium dodecyl sulfate, 1 mM
Na3VO4, and protease inhibitor cocktail (Nacalai tesque,
Kyoto, Japan) for 30 min on ice and centrifuged at
15,000 rpm for 20 min at 4°C. Proteins were separated
by 10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred onto a polyvi-
nylidene fluoride (PVDF) membrane. The membranes
were incubated overnight at 4°C with rabbit primary
antibodies against type 1 PTH/PTHrP receptor (PTH1R)
(LifeSpan Biosciences, Seattle, WA, USA), SRY-box9
(Sox9) (Millipore, Temecula, CA, USA), Runt-related
transcription factor 2 (Runx2) (Novus Biologicals, Little-
ton, CO, USA) and β-actin (Novus Biologicals). The
membranes were washed and incubated with horserad-
ish peroxidase labeled anti-rabbit IgG (Kirkegaard and
Perry Laboratories, Gaithersburg, MD, USA) for 60 min
at room temperature. After a washing step, bands were
visualized by ECL Prime Western blotting detection re-
agent (GE Healthcare, Piscataway, NJ, USA) and ana-
lyzed using a luminescent image analyzer equipped with
a cooled CCD camera (LAS 1000, Fujifilm, Tokyo,
Japan).
Total RNA isolation and RT-PCR
Total RNA was isolated from homogenized pellets using
Trizol reagent (Invitrogen, Carlsbad, CA, USA). RNA
was quantified by measuring absorbance at 260 nm, and
the quality was assessed by determining the 260/280 nm
absorbance ratio. First-strand cDNA synthesis was per-
formed with 0.5 μg or 1 μg total RNA in a total volume
of 20 μl using an iScript™ advanced cDNA synthesis kit
(BIO-RAD, Richmond, CA, USA). Gene expressions of
collagen type II α1 chain (Col2a1), collagen type X α1
chain (Col10a1), collagen type I α1 chain (Col1a1), Sox9,
and PTH1R were examined with quantitative real-time
PCR. The primers used in this study were listed in
Table 1. Quantitative real-time PCR was carried out
using SsoAdvanced™ SYBR Green supermix (BIO-RAD)
Table 1 Primers used for real-time RT-PCR
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RAD) in a 20-μl reaction volume. Expression of gene of
interest was normalized to GAPDH expression.
Statistical analysis
All experiments were repeated at least three independ-
ent times. All data are presented as the mean ± SEM.
The analysis was done using SigmaStat 3.5 software
(Systat Software Inc., Richmond, CA, USA). The non-
parametric Kruskal-Wallis test was used to test for
significant differences among the test groups. When aFigure 1 Histological findings of chondrogenic pellet cultures of MSC
Blue staining, and lower panels (F–J) show immunohistochemical staining
0.1 (B, G), 1 (C, H), 10 (D, I), or 100 nM (E, J). Immunohistochemical stainin
(K) and normal rabbit IgG (L, as a negative control). Note that no backgrou
IgG. Scale bars = 100 μm.significant difference was detected, Steel's post hoc test
was performed to compare each of the treatments with a




Chondrogenic differentiation was confirmed with Alcian
Blue staining for proteoglycan synthesis. Positive staining
with Alcian Blue was identified in all treatment groups
(Figure 1A,B,C,D,E). Among the groups, stronger stain-
ing was observed with 1 and 10 nM PTH, whereas less
intense staining was seen with 100 nM PTH. Regarding
cellular morphology, sections from cells treated with 10
nM PTH exhibited more chondrocyte-like cells with
large round nuclei than cells treated with 100 nM PTH.
To further address chondrogenic differentiation, we
examined the deposition of type II collagen, which is a
major component of the cartilage extracellular matrix
(Figure 1F,G,H,I,J). Expression of type II collagen was
partially localized in 0 nM PTH control. Improved
expression was found in 10 nM PTH. In contrast, almost
negative expression was shown in 100 nM PTH.
Effect of PTH on protein expression in chondrogenic
differentiation
Protein expressions of PTH1R, Sox9, and Runx2 were de-
tected by Western blotting (Figure 2). Positive expressions treated with PTH for 21 days. Upper panels (A–E) show Alcian
of collagen type II. PTH was administrated at various doses: 0 (A, F),
g of mouse cartilage tissue using anti-collagen type II antibody
nd staining is observed in the section incubated with normal rabbit
Figure 2 Effect of PTH on protein expression in chondrogenic
pellet culture for 21 days. Expression of PTH1R, Sox9, and Runx2 in
various concentrations of PTH was analyzed using Western blotting.
Figure 3 Effect of PTH on collagen expression in chondrogenic
pellet culture for 3, 7, and 21 days. Relative mRNA levels of
Col2a1 (A), Col10a1 (B), and Col1a1 (C) following PTH treatment are
compared with expression in the control (0 nM PTH) (n = 8 for each
dose). *P < 0.05 vs. control group (Steel's test).
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whereas the intensity was remarkably reduced in 100 nM
PTH. Protein expression of Sox9, a master regulator of
chondrogenesis, was identified 3 weeks after chondro-
genic differentiation from MSCs. Strong bands were
present in 1 and 10 nM PTH and less intense one in
100 nM. Runx2, a transcription factor that promotes
chondrocyte hypertrophy, was not intensely expressed in
any PTH concentration.
Effect of PTH on collagen expression in early stage of
chondrogenic differentiation
To determine whether PTH modulates the early stage of
chondrogenic differentiation of MSCs, gene expression
of type II collagen as a marker of chondrogenesis was
analyzed when cells were treated with various doses of
PTH (Figure 3A). Relative mRNA expression of Col2a1
was significantly reduced with 100 nM PTH at days 3, 7,
and 21 (P < 0.05, vs. 0 nM PTH). In contrast, treatment
with 1 and 10 nM PTH resulted in significantly in-
creased expression of Col2a1 at days 7 and 21 (P < 0.05,
vs. 0 nM PTH). To assess the phenotypic change of
hypertrophy during chondrogenesis of MSCs, gene ex-
pression of type X collagen as a marker of chondrogenic
hypertrophy was also examined (Figure 3B). Relative
mRNA expression of Col10a1 was not significantly chan-
ged with different doses of PTH at days 3, 7, and 21. To
further characterize the effect of PTH on chondrogenic
differentiation of MSCs, gene expression of type I collagen
as a marker of hypertrophic or osteogenic differentiation
was investigated (Figure 3C). We observed no significant
difference in relative mRNA expression levels of Col1a1 at
days 3, 7, and 21 among the various dose groups.
Effect of PTH on activation of Sox9 and PTH receptor
during chondrogenic differentiation of MSCs
To assess the effect of PTH on the key transcription factor
involved in chondrogenic differentiation, gene expressionof Sox9 was analyzed (Figure 4A). Relative mRNA expres-
sion of Sox9 was significantly diminished in the presence
of 100 nM PTH after days 3 and 21 (P < 0.05, vs. 0 nM
PTH). In contrast, significantly increased levels of Sox9
were seen with 0.1 nM PTH at day 7, and 1 and 10 nM
PTH at days 7 and 21 (P < 0.05, vs. 0 nM PTH). These ex-
pression patterns of Sox9 among the various doses were
similar to those of Col2a1. To determine if the receptor is
upregulated in response to PTH administration, gene
expression of the PTH receptor was examined (Figure 4B).
Relative mRNA expression of PTH1R was significantly
Figure 4 Effect of PTH on transcription factor involved in
chondrogenic differentiation and response of PTH receptor. In
chondrogenic pellet culture for 3, 7, and 21 days. Relative mRNA
levels of Sox9 (A) and PTH1R (B) following PTH treatment are
compared with expression in the control (0 nM PTH) (n = 8 for each
dose). *P < 0.05 vs. control group (Steel's test).
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vs. 0 nM PTH). In contrast, PTH1R was significantly in-
creased with 1 and 10 nM PTH at days 7 and 21 (P < 0.05,
vs. 0 nM PTH). The expression patterns for PTH1R were
very similar to those for Sox9 and Col2a1.
Discussion
The present study demonstrated that chondrogenic differ-
entiation of MSCs was modulated by PTH. The results
revealed that PTH has opposite effects on chondrogenesis
when administered at different concentrations. Namely,
low to moderate concentrations of PTH promoted chon-
drogenic differentiation of MSCs, whereas chondrogenesis
of MSCs was inhibited and not stimulated by a higher
concentration of PTH.
This study was intended to test the hypothesis that
PTH has a stimulatory effect on chondrogenic differenti-
ation. An effect on induction of chondrogenesis with in-
creased collagen type II was previously confirmed using
a single concentration of PTH in growth plate chondro-
cytes [13] and MSCs from osteoarthritis patients [15]. In
contrast, the inhibitory function of PTH on chondrocyte
hypertrophy has been shown with reduced expression ofcollagen type X under conditions that promote chondro-
genic differentiation [15,16]. The constitutive expression
of the PTH/PTHrP receptor in a bone morphogenetic
protein-dependent differentiation system leads to a marked
stimulation of chondrogenic and osteogenic development,
whereas permanent application of the ligand PTH(1–34)
results in opposite responses by stimulating the early and
suppressing the late stages of osteo-/chondrogenic devel-
opment [17]. These contrasting effects of PTH(1–34) on
osteogenic and chondrocytic development seem to depend
on the cellular state of differentiation. Our results were
partially consistent with those previous reports. However,
different from previous reports, we observed that expres-
sion of both Col2a1 and PTH1R was suppressed by a
higher concentration of PTH. To our knowledge, no
supportive studies have been published showing that the
response to PTH during chondrogenic differentiation is
opposite depending on a lower or higher concentration.
Therefore, the modulatory effect of PTH on chondrogenic
differentiation is likely to remain controversial.
PTH and PTHrP show homology in the amino-
terminal (1–34) peptide fragments with high-affinity
binding to PTH1R. Biological responses elicited by either
ligand through this common PTH1R are largely indistin-
guishable, at least with regard to mineral ion homeosta-
sis [18]. According to Weiss and colleagues [19], adding
0.1 ng/mL of PTHrP beginning on day 21 could sup-
press collagen type X deposition without any negative
effects on chondrogenic differentiation, whereas higher
concentrations (10 or 100 ng/mL) or earlier treatment
(from day 0) would lead to the suppression of chondro-
genesis. These contradictory effects of PTHrP on chon-
drogenic differentiation seem to be applicable to PTH
on the basis of high similarity in the biological function
[20]. Physicians may be interested in PTH rather than
PTHrP because the former is currently available for clin-
ical application. Therefore, several issues regarding the
efficacy of PTH administration for successful cartilage
repair need to be investigated further, including optimiza-
tion of the concentration, treatment timing, and delivery
method. The advantage of this study is that the investiga-
tions included a concentration-response range and exam-
ination of changes in expression of the exact genes.
The transcription factor Sox9 has been demonstrated to
be a master regulator of the differentiation of mesenchy-
mal cells into chondrocytes [21,22]. The TGF-β signal
plays an essential role to induce primary chondrogenesis
[4,23], which is mediated by up-regulation of Sox9 [24].
Furthermore, Sox9 is a target of PTH/PTHrP receptor sig-
naling to maintain the chondrocyte phenotype and inhibit
their maturation to hypertrophic chondrocytes in the
growth plate [25]. Our results support the idea of a PTH/
PTHrP receptor signal-dependent increase in Sox9 ex-
pression during chondrogenic differentiation from MSCs.
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concentration and timing for administration of PTH.
Physiological PTH concentrations are much lower than
those used in this study. However, in a number of
in vitro studies examining the efficacy of PTH, the con-
centration tested is usually out of therapeutic ranges
[9,12,13,15,16]. The response to PTH administration
increases in a concentration-dependent manner, and the
minimum effective concentration is higher than physio-
logical levels [13,26]. Therefore, we have chosen concen-
trations that significantly altered the cellular response
and that showed the expected efficacy. The ability to
reflect clinical relevance with cell culture models is diffi-
cult due to the lack of physiological conditions once
cells are isolated from tissues and organs. The question
is whether the output response is supportive of our
understanding of the biology that will lead to decisions
regarding translation of appropriate concentrations for
assessment in human clinical testing. Furthermore, the
relationship between the timing of exposure and the effi-
cacy is unclear because PTH was continuously adminis-
tered throughout the experimental period. For clinical
use, PTH is intermittently administered when utilized
for bone anabolic effects. Whether intermittent adminis-
tration rather than continuous administration is effective
for cartilage induction remains to be determined. This
point is especially important for direct administration
for therapeutic use. Further studies are required to ex-
trapolate the translatable efficacy and safety in humans.
For current therapeutic application, indirect treatment
of human organ systems ex vivo, such as treatment prior
to cell implantation, seems rational.
Conclusions
This study provides insight into the modulatory effect of
PTH on chondrogenic differentiation from MSCs. Ideal
repair of injured cartilage involves replacement with hya-
line cartilage and prevention of osteoarthritic changes.
Several animal studies have shown that PTH has thera-
peutic potential for cartilage regeneration and protection
as well as inhibition of progression of osteoarthritis
[9,10,14]. PTH(1–34) has a stimulatory effect on bone
formation with intermittent administration and is cur-
rently used as an anabolic drug for treatment of osteo-
porosis. Based on clinical experience with the efficacy
and safety of PTH for bone metabolism, PTH may also
be clinically useful for cartilage repair.
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